Role of interleukin-2 in patients with HIV infection (Q37762244)

22 August 2017

1 reference

title

Role of interleukin-2 in patients with HIV infection (English)

1 reference

22 August 2017

0 references

0 references

Sarah L Pett

1

1 reference

22 August 2017

Anthony D Kelleher

series ordinal

2

1 reference

22 August 2017

Sean Emery

series ordinal

3

1 reference

22 August 2017

publication date

1 June 2010

1 reference

22 August 2017

1 reference

22 August 2017

volume

70

1 reference

22 August 2017

issue

9

1 reference

22 August 2017

page(s)

1115-1130

1 reference

https://scigraph.springernature.com/pub.10.2165/10898620-000000000-00000

22 August 2017

exact match

0 references

cites work

Randomized, open-label study of the impact of two doses of subcutaneous recombinant interleukin-2 on viral burden in patients with HIV-1 infection and CD4+ cell counts of > or = 300/mm3: CPCRA 059.

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F10898620-000000000-00000

Surrogate end points in clinical trials: are we being misled?

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F10898620-000000000-00000

Disease progression in patients with virological suppression in response to HAART is associated with the degree of immunological response

21 January 2018

1 reference

12 December 2020

The virologic, immunologic, and clinical effects of interleukin 2 with potent antiretroviral therapy in patients with moderately advanced human immunodeficiency virus infection: a randomized controlled clinical trial--AIDS Clinical Trials Group 328.

1 reference

12 December 2020

Interleukin-2 cycling causes transient increases in high-sensitivity C-reactive protein and D-dimer that are not associated with plasma HIV-RNA levels

1 reference

12 December 2020

Inferiority of IL-2 alone versus IL-2 with HAART in maintaining CD4 T cell counts during HAART interruption: a randomized controlled trial

1 reference

12 December 2020

Immunotherapy with canarypox vaccine and interleukin-2 for HIV-1 infection: termination of a randomized trial

1 reference

12 December 2020

Enhanced T cell recovery in HIV-1-infected adults through IL-7 treatment

1 reference

12 December 2020

Immunological and virological efficacy of a therapeutic immunization combined with interleukin-2 in chronically HIV-1 infected patients.

1 reference

12 December 2020

Long-term effects of intermittent interleukin-2 therapy in chronic HIV-infected patients (ANRS 048-079 Trials)

1 reference

12 December 2020

Interleukin 2 enhances the natural killer cell activity of acquired immunodeficiency syndrome patients through a gamma-interferon-independent mechanism

1 reference

12 December 2020

Class of Antiretroviral Drugs and the Risk of Myocardial Infarction

1 reference

12 December 2020

Safety, Tolerability, Pharmacokinetics, and Efficacy of an Interleukin-2 Agonist Among HIV-Infected Patients Receiving Highly Active Antiretroviral Therapy

1 reference

12 December 2020

Subcutaneous administration of interleukin-2 in human immunodeficiency virus type 1-infected persons

1 reference

12 December 2020

Increased turnover of T lymphocytes in HIV-1 infection and its reduction by antiretroviral therapy

1 reference

12 December 2020

TILT: a randomized controlled trial of interruption of antiretroviral therapy with or without interleukin-2 in HIV-1 infected individuals

1 reference

12 December 2020

CD4 T cell survival after intermittent interleukin-2 therapy is predictive of an increase in the CD4 T cell count of HIV-infected patients

1 reference

12 December 2020

Intensification and stimulation therapy for human immunodeficiency virus type 1 reservoirs in infected persons receiving virally suppressive highly active antiretroviral therapy

1 reference

12 December 2020

A randomized, double-blinded, placebo-controlled trial of intermittent administration of interleukin-2 and prednisone in subjects infected with human immunodeficiency virus

1 reference

12 December 2020

The effect of continuous versus pericycle antiretroviral therapy on IL-2 responsiveness

1 reference

12 December 2020

Interleukin-2 before antiretroviral therapy in patients with HIV infection: a randomized trial (ANRS 119).

1 reference

12 December 2020

CD4 cell response to 3 doses of subcutaneous interleukin 2: meta-analysis of 3 Vanguard studies

1 reference

12 December 2020

Outpatient continuous intravenous interleukin-2 or subcutaneous, polyethylene glycol-modified interleukin-2 in human immunodeficiency virus-infected patients: a randomized, controlled, multicenter study. Australian IL-2 Study Group

1 reference

12 December 2020

Cytokine therapies in HIV-1 infection: present and future

1 reference

12 December 2020

IL-2-induced CD4+ T-cell expansion in HIV-infected patients is associated with long-term decreases in T-cell proliferation

1 reference

12 December 2020

HIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: a collaborative analysis

1 reference

12 December 2020

HIV-1 gp120 and anti-gp120 induce reversible unresponsiveness in peripheral CD4 T lymphocytes.

1 reference

12 December 2020

Immune restoration does not invariably occur following long-term HIV-1 suppression during antiretroviral therapy. INCAS Study Group.

1 reference

12 December 2020

The potential for CD4 cell increases in HIV-positive individuals who control viraemia with highly active antiretroviral therapy

1 reference

12 December 2020

Sustained control of viremia following therapeutic immunization in chronically HIV-1-infected individuals

1 reference

12 December 2020

Induction and maintenance therapy with intermittent interleukin-2 in HIV-1 infection

1 reference

12 December 2020

Comparison of subcutaneous and intravenous interleukin-2 in asymptomatic HIV-1 infection: a randomised controlled trial. ANRS 048 study group.

1 reference

12 December 2020

Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study.

1 reference

12 December 2020

Interruption of Antiretroviral Therapy Initiated during Primary HIV-1 Infection: Impact of a Therapeutic Vaccination Strategy Combined with Interleukin (IL)-2 Compared with IL-2 Alone in the ANRS 095 Randomized Study

1 reference

12 December 2020

CD4+ count-guided interruption of antiretroviral treatment

1 reference

12 December 2020

Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies

1 reference

12 December 2020

Immunotherapy of HIV-infected patients with intermittent interleukin-2: effects of cycle frequency and cycle duration on degree of CD4(+) T-lymphocyte expansion

1 reference

12 December 2020

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

1 reference

12 December 2020

Immunological recovery and antiretroviral therapy in HIV-1 infection

1 reference

12 December 2020

Effects of interleukin-2 therapy combined with highly active antiretroviral therapy on immune restoration in HIV-1 infection: a randomized controlled trial

1 reference

12 December 2020

Toward HIV eradication or remission: the tasks ahead

1 reference

12 December 2020

AIDS research. Promising AIDS vaccine's failure leaves field reeling

1 reference

12 December 2020

IL-2, IL-7 and IL-15 as immuno-modulators during SIV/HIV vaccination and treatment

1 reference

12 December 2020

Effects of intermittent IL-2 alone or with peri-cycle antiretroviral therapy in early HIV infection: the STALWART study

1 reference

12 December 2020

Immune activation and AIDS pathogenesis

1 reference

12 December 2020

Cumulative HIV viremia during highly active antiretroviral therapy is a strong predictor of AIDS-related lymphoma

1 reference

12 December 2020

Recovery of replication-competent HIV despite prolonged suppression of plasma viremia

1 reference

12 December 2020

HIV Diagnosis at CD4 Count Above 500 Cells/mm3 and Progression to Below 350 Cells/mm3 Without Antiretroviral Therapy

1 reference

12 December 2020

Effective therapy has altered the spectrum of cause-specific mortality following HIV seroconversion

1 reference

12 December 2020

An evaluation of HIV RNA and CD4 cell count as surrogates for clinical outcome. Delta Coordinating Committee and Virology Group

1 reference

12 December 2020

Effects of interleukin-2 plus highly active antiretroviral therapy on HIV-1 replication and proviral DNA (COSMIC trial).

1 reference

12 December 2020

Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration

1 reference

12 December 2020

Interleukin-2 therapy in patients with HIV infection

1 reference

12 December 2020

CD4 Cell Counts of 800 Cells/mm3 or Greater After 7 Years of Highly Active Antiretroviral Therapy Are Feasible in Most Patients Starting With 350 Cells/mm3 or Greater

1 reference

12 December 2020

Molecular characterization of interleukin 2

1 reference

12 December 2020

HIV-infected adults with a CD4 cell count greater than 500 cells/mm3 on long-term combination antiretroviral therapy reach same mortality rates as the general population

1 reference

12 December 2020

A randomized, controlled, phase II trial comparing escalating doses of subcutaneous interleukin-2 plus antiretrovirals versus antiretrovirals alone in human immunodeficiency virus-infected patients with CD4+ cell counts >/=350/mm3.

1 reference

12 December 2020

A randomized, controlled 24-week study of intermittent subcutaneous interleukin-2 in HIV-1 infected patients in Thailand

1 reference

12 December 2020

Effect of interleukin-2 on the pool of latently infected, resting CD4+ T cells in HIV-1-infected patients receiving highly active anti-retroviral therapy

1 reference

12 December 2020

An HIV vaccine--evolving concepts

1 reference

12 December 2020

Immunosuppression by glucocorticoids: inhibition of NF-kappa B activity through induction of I kappa B synthesis

1 reference

12 December 2020

Increased peripheral expansion of naive CD4+ T cells in vivo after IL-2 treatment of patients with HIV infection

1 reference

12 December 2020

Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients

1 reference

12 December 2020

Pooled analysis of 3 randomized, controlled trials of interleukin-2 therapy in adult human immunodeficiency virus type 1 disease

1 reference

12 December 2020

1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults

1 reference

12 December 2020

A randomized, partially blinded phase 2 trial of antiretroviral therapy, HIV-specific immunizations, and interleukin-2 cycles to promote efficient control of viral replication (ACTG A5024).

1 reference

12 December 2020

CD4 cell count as a surrogate endpoint in HIV clinical trials: a meta-analysis of studies of the AIDS Clinical Trials Group

1 reference

12 December 2020

Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy

1 reference

12 December 2020

Interruption of antiretroviral therapy blunts but does not abrogate CD4 T-cell responses to interleukin-2 administration in HIV infected patients

1 reference

12 December 2020

Differential Th17 CD4 T-cell depletion in pathogenic and nonpathogenic lentiviral infections

1 reference

12 December 2020

A randomized controlled trial evaluating the efficacy and safety of intermittent 3-, 4-, and 5-day cycles of intravenous recombinant human interleukin-2 combined with antiretroviral therapy (ART) versus ART alone in HIV-seropositive patients with 10

1 reference

12 December 2020

Normalisation of CD4 counts in patients with HIV-1 infection and maximum virological suppression who are taking combination antiretroviral therapy: an observational cohort study

1 reference

12 December 2020

Immunological and virological effects of long term IL-2 therapy in HIV-1-infected patients

1 reference

12 December 2020

Microbial translocation is a cause of systemic immune activation in chronic HIV infection

1 reference

12 December 2020

Interleukin-2 accelerates CD4 cell reconstitution in HIV-infected patients with severe immunosuppression despite highly active antiretroviral therapy: the ILSTIM study--ANRS 082.

1 reference

12 December 2020

Tumor necrosis factor alpha and interleukin 1 stimulate the human immunodeficiency virus enhancer by activation of the nuclear factor kappa B

1 reference

12 December 2020

A randomised trial of subcutaneous intermittent interleukin-2 without antiretroviral therapy in HIV-infected patients: the UK-Vanguard Study

1 reference

12 December 2020

Immunologic and virologic effects of subcutaneous interleukin 2 in combination with antiretroviral therapy: A randomized controlled trial

1 reference

12 December 2020

Interleukin-2: inception, impact, and implications

1 reference

12 December 2020

CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression.

1 reference

12 December 2020

Effect of early versus deferred antiretroviral therapy for HIV on survival

1 reference

12 December 2020

CD4+T Cell Responses to Interleukin‐2 Administration in HIV‐Infected Patients Are Directly Related to the Baseline Level of Immune Activation

1 reference

12 December 2020

HIV infection induces changes in CD4+ T-cell phenotype and depletions within the CD4+ T-cell repertoire that are not immediately restored by antiviral or immune-based therapies

1 reference

12 December 2020

Controlled trial of interleukin-2 infusions in patients infected with the human immunodeficiency virus

1 reference

12 December 2020

The evaluation of subcutaneous proleukin (interleukin-2) in a randomized international trial: rationale, design, and methods of ESPRIT.

1 reference

12 December 2020

Inflammatory and coagulation biomarkers and mortality in patients with HIV infection

1 reference

12 December 2020

A model for the selective loss of major histocompatibility complex self-restricted T cell immune responses during the development of acquired immune deficiency syndrome (AIDS).

1 reference

12 December 2020

HIV-1 rebound after anti-retroviral therapy

1 reference

12 December 2020

IL-7 administration drives T cell-cycle entry and expansion in HIV-1 infection

1 reference

12 December 2020

A randomized trial of high- versus low-dose subcutaneous interleukin-2 outpatient therapy for early human immunodeficiency virus type 1 infection

1 reference

12 December 2020

Effect of baseline- and treatment-related factors on immunologic recovery after initiation of antiretroviral therapy in HIV-1-positive subjects: results from ACTG 384.

1 reference

12 December 2020

Induction of prolonged survival of CD4+ T lymphocytes by intermittent IL-2 therapy in HIV-infected patients

1 reference

12 December 2020

Therapeutic vaccines for chronic infections

1 reference

12 December 2020

Efficacy of low-dose intermittent subcutaneous interleukin (IL)--2 in antiviral drug--experienced human immunodeficiency virus--infected persons with detectable virus load: a controlled study of 3 il-2 regimens with antiviral drug therapy.

1 reference

12 December 2020

Long-term effects of intermittent interleukin 2 therapy in patients with HIV infection: characterization of a novel subset of CD4(+)/CD25(+) T cells

1 reference

12 December 2020

Closeout of four phase II Vanguard trials and patient rollover into a large international phase III HIV clinical endpoint trial.

1 reference

12 December 2020

10.2165/10898620-000000000-00000

Identifiers

DOI

1 reference

Dimensions Publication ID

22 August 2017

1014949128

0 references

1 reference